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ORIGINAL ARTICLE
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a
b

Division of Cardiology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China

Abstract
Background: The ‘inﬂamm-ageing’ phenomenon may worsen the prognosis of heart diseases including infective
endocarditis (IE), while surgery may reduce inﬂammatory burden by direct removal of bacterial vegetation. This study
aims to characterize the epidemiological and clinical features of surgical intervention for IE in Hong Kong in the past
two decades.
Methods: All patients with incident IE from 2000 to 2019 in a territory-wide database were identiﬁed. We studied the
trends in age-speciﬁc incidence of IE and identiﬁed the most signiﬁcant contributors to 1-year all-cause death using the
population attributable fraction (PAF). A propensity score approach was used to evaluate the beneﬁts of surgical
intervention.
Results: A total of 5657 patients (mean age 60 years, 37% women) were included. Patients have become older, with an
increasing trend in mean age from 2000 to 2019 (annual percentage change [APC] 0.9%, 95% CI 0.8 to 1.1, P < 0.001).
Surgical intervention was associated with a 45% risk reduction in 1-year all-cause mortality (Hazard Ratio 0.55
[0.45e0.66], P < 0.001), with consistent results across patient subgroups. Advanced age (PAF 19%) and comorbidities
(PAF 18%) were signiﬁcant contributors to death, regardless of the time period; the PAF of surgical intervention
increased over time, indicating its increasing beneﬁts.
Conclusions: Patients with IE have become older in the past two decades, while surgical intervention signiﬁcantly
improved survival. Our results may help to improve outcomes of patients with IE by informing public health and
clinical decisions.
Keywords: Infective endocarditis, Epidemiology, Surgical intervention, Ageing, Inﬂamm-ageing

Introduction

I

nfective endocarditis (IE) is associated with signiﬁcant mortality and morbidity [1e8]. Common

risk factors include previous implantation of prosthetic valve or cardiac device and bacteraemia due
to iatrogenic causes (e.g. hospital-acquired endocarditis) or relative immunodeﬁciencies (e.g.
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diabetes mellitus). The prevalence of these risk
factors is expected to increase further given the
ageing population worldwide [6,9]. In recent years,
the ‘inﬂamm-ageing’ phenomenon, whereby there
is a heightening inﬂammatory burden amongst the
ageing population, has been increasingly recognized [9]. This is particularly relevant to the population at risk of IE, as previous studies have
consistently demonstrated the adverse prognosis
conferred by inﬂammation once IE is diagnosed
[10e15].
In patients with IE, the microbial vegetation
serves as the culprit substrate driving inﬂammatory
processes. It can be relieved by direct excision of the
vegetation that also permits immediate alleviation/
reversal of the valvular defect(s) and the associated
atrial/ventricular dilation/pressure overload before
patients develop clinically overt complications such
as heart failure (HF). However, the beneﬁts of surgical intervention in the context of IE have yet to be
comprehensively evaluated in a large, representative population. The generalizability of surgery's
efﬁcacy in the population of IE patients with highly
variable patient characteristics remains understudied. In particular, our previous study has shown
that advanced age and the attendant comorbidities
were the most signiﬁcant contributors to adverse
prognosis [6], but the utility of surgical intervention
has yet to be investigated in these particularly susceptible patients. Given these signiﬁcant knowledge
gaps, the objectives of this study were to ﬁrst
describe the clinical characteristics of IE patients in
terms of age, and second to comprehensively evaluate the beneﬁts of surgical intervention in a large
Asian cohort of IE patients.

Methods
Data source
This study used data from the Clinical Data
Analysis Reporting System (CDARS), a territorywide database developed by the Hong Kong Hospital Authority since January 1, 1993. The Hospital
Authority is the sole public healthcare provider in
Hong Kong, covering >80% of secondary and tertiary care in Hong Kong with a population of around
7.5 million [16,17]. Patients’ clinical information,
including demographics, diagnoses, blood tests, and
surgical treatments, were prospectively recorded in
CDARS. Previous high-quality population-based
studies have validated the coding accuracy of
CDARS [16e18]. Details about CDARS are provided
in Supplementary Table 1 (https://www.jhkcc.com.
hk/cgi/editor.cgi?article¼1485&window¼additional_
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ﬁles&context¼journal). The institutional review
board of The University of Hong Kong and the West
Cluster of Hong Kong Hospital Authority has
approved this study (UW 20e819). We have previously described the epidemiological and clinical
characteristics of IE patients in Hong Kong using the
same CDARS cohort [6].
Participants
We included all patients aged 20 or above newly
diagnosed with IE between January 1, 2000, and
December 31, 2019. We adopted a look-back period
of 7 years to minimize the risk of recurrent episodes
of IE from being deﬁned as the incident episode.
The diagnosis of IE was deﬁned using International
Classiﬁcation of Diseases 9 (ICD-9) codes (Supplementary Table 1 (https://www.jhkcc.com.hk/cgi/
editor.cgi?article¼1485&window¼additional_ﬁles&
context¼journal)). In our validation exercise, there
was a high diagnostic accuracy with a positive predictive value of 88.8% (95% conﬁdence interval [CI]
84.8 to 92.9), which was comparable to that in previous studies [2,4] (Supplementary Text 2 (https://
www.jhkcc.com.hk/cgi/editor.cgi?article¼1485&
window¼additional_ﬁles&context¼journal)).
We extracted demographic information (age, sex),
aetiology of IE, comorbidities, clinical course during
hospitalisation, blood culture and sensitivity testing
information, mode of acquisition, and information
on death (death status and date) for each IE patient.
The ICD-9 codes used for deﬁning the comorbidities, aetiology, and mode of acquisition were shown
in Supplementary Table 1 (https://www.jhkcc.com.
hk/cgi/editor.cgi?article¼1485&window¼additional
_ﬁles&context¼journal). The hierarchical algorithms used to deﬁne aetiology, mode of acquisition,
and causative organism were shown in Supplementary Figure 1 (https://www.jhkcc.com.hk/cgi/
editor.cgi?article¼1485&window¼additional_ﬁles&
context¼journal).
The primary outcome was 1-year all-cause mortality. Patient follow-up was censored at the date of
occurrence of the outcome of interest, death, or end
of the study (December 31, 2020).
Statistical analysis
Baseline characteristics (demographics, comorbidities including the modiﬁed Charlson Comorbidity Index [CCI] [19], aetiology of IE, predisposing
factors, causative organism, mode of acquisition)
were summarized by 5 calendar year groups. All
statistical tests for temporal trends were evaluated
using individual years, instead of calendar year
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groups. For descriptive analysis, continuous variables were reported as means ± standard deviations
(mean ± SD), while categorical variables were reported as proportions out of the total number of IE
cases. Trends in baseline patient characteristics were
evaluated using Log-Linear Poisson regression and
the APC was reported; linear regression was used to
evaluate the trends in patient age and CCI [4].
The crude incidence of IE was calculated by
dividing the number of patients with incident IE
each year by the total population of Hong Kong
(speciﬁc to the age group concerned) [20]. To account for changes in sex in the population, direct
standardisation was applied with the population in
2000 as the reference. To evaluate the temporal
trends in the age-speciﬁc incidence of IE, Poisson
regression analysis adjusted for age (exact value of
age in years within the speciﬁc age group) and sex
was performed. To allow for over-dispersion, a
scaling factor (quasi-Poisson) was used [2]. Trends
in incidence were assessed by annual percentage
change (APC).
To evaluate the survival beneﬁt of surgical intervention, a propensity score approach was used to
reduce bias due to lack of randomisation in treatment allocation. Covariates included variables that
were considered prognostically signiﬁcant or those
that inﬂuenced treatment selection, including demographics, comorbidities, aetiology, microbiology,
and mode of acquisition, which were used to estimate the probability of receiving surgery using covariate balancing propensity score [21,22]. An
inverse propensity of treatment weighting (IPTW)
was used. The differences in the prevalence of
covariates were considered signiﬁcant if the standardized mean difference (SMD) was 0.10. A Cox
proportional-hazards model was used to evaluate
the relative risk of 1-year all-cause death in patients
who received surgical intervention compared to
those who did not. A sensitivity analysis using
“doubly-robust estimation”, where covariates used
in calculating the propensity score were further
adjusted for, was performed to minimize confounding [21]. Subgroup analyses according to age,
CCI, and year of diagnosis were performed. Temporal trends in surgical intervention over time were
evaluated using Poisson regression analysis. We
compared the regimens and length of antibiotic
treatment between the surgery vs non-surgery
groups and evaluated whether these factors affected
the beneﬁts of surgery by additionally adjustment in
the Cox regression model. As a supplementary
analysis to evaluate whether the beneﬁts of surgery
varied according to timing of intervention, we

employed a time-varying analysis by modelling
surgery as a time-varying variable to circumvent
immortal time bias [6,23].
Using a hazard risk approach, a population
attributable fraction (PAF) analysis was performed
to evaluate the contribution of age, CCI, comorbidities, causative organism, aetiology, mode of acquisition, and surgical intervention to 1-year all-cause
death. The changes in PAF of 1-year death attributable to surgical intervention over time were also
evaluated. All tests were 2-tailed, and statistical
signiﬁcance was deﬁned as P < 0.05. All statistical
analyses were performed using R (v4.0.4).

Results
Study population
A total of 5657 patients (age 59.9 ± 18.3 years; 2102
[37.2%] female) diagnosed with incident IE were
identiﬁed from 2000 to 2019 (Table 1). The
mean ± SD of age increased from 55.6 ± 18.4 in
2000e2003 to 64.2 ± 17.5 years in 2016e2019 (APC
0.9%, 95% CI 0.8 to 1.1, P < 0.001). Majority of the
patients in our locality had native-valve endocarditis
(92.0%). A total of 79 (1.4%) of patients had fungal
endocarditis. The proportion of patients aged 60e79
and  80 years increased signiﬁcantly, with APC of
1.7% (95% CI 1.1 to 2.4, P < 0.001) and 5.1% (95% CI
4.0 to 6.2, P < 0.001), respectively.
Incidence
The overall incidence and the temporal trends in
incidence according to age were shown in Table 2.
The age group 80 years had the highest overall
incidence (17.2 per 100,000 person-year), while the
20e39 years age group had the lowest overall incidence (2.4 per 100,000 person-year). After adjustment for age and sex, the incidence of IE decreased
signiﬁcantly in the 20e39 years (APC -2.7, 95% CI
-3.7 to 1.6, P < 0.001) and 40e59 years (APC -1.8,
95% CI -2.7 to 1.0, P < 0.001) age groups, and
remained unchanged in the 60e79 years (APC 0.0%,
95% CI -1.0 to 1.0, P ¼ 0.979) and 80 years (APC
0.6%, 95% CI -0.5 to 1.8, P ¼ 0.263) age groups.
Surgical intervention
A total of 936 (16.4%) patients underwent surgical
intervention within 1 year. The rate of surgical
intervention increased signiﬁcantly in the past two
decades (APC 2.8%, 95% CI 1.8 to 3.9, P < 0.001). Patients who received surgical intervention were
younger, with less comorbid (lower prevalence of
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Table 1. Temporal trends in patient characteristics from 2000 through 2019.

cardiovascular diseases [hypertension, heart failure,
myocardial infarction, cerebrovascular disease], diabetes mellitus, and renal impairment), and more
likely to have chronic rheumatic heart disease and
community-acquired infection. For both the surgical
and non-surgical cohorts, baseline covariates were
well-balanced upon IPTW (Table 3). Among patients
who received (N ¼ 936) and did not receive (N ¼ 4721)
surgery, 138 (14.8%) and 1653 (35.0%) patients died
within 1-year, respectively. After IPTW, surgical
intervention was associated with a 45% risk reduction
in 1-year all-cause mortality (HR 0.55, 95% CI 0.46 to
0.66, P < 0.001) (Figure 1). Sensitivity analysis with

‘doubly-robust’ estimation showed consistent results
(Supplementary Table 2 (https://www.jhkcc.com.hk/
cgi/editor.cgi?article¼1485&window¼additional_
ﬁles&context¼journal)). For both the surgery and
non-surgery groups, the majority received penicillingroup antibiotics; the surgery group was more likely
to receive aminoglycosides (63.7% vs 43.0%), vancomycin (37.0% vs 23.0%), and macrolides (12.6% vs
8.6%). The mean durations of medical treatment in
the surgery and non-surgery groups were 27.4 and
24.5 days, respectively. Further adjustment for the
regimen and length of antibiotic treatment revealed
consistent survival beneﬁt conferred by surgery (HR
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Table 2. Trends in incidence of infective endocarditis by age.

0.46, 95% CI 0.38 to 0.55, P < 0.001). When surgical
intervention was modelled as a time-varying exposure to circumvent possible immortal time bias, it
consistently reduced risk of all-cause mortality by
55% (HR 0.46, 95% CI 0.38 to 0.56, P < 0.001).
The results of subgroup analysis are shown in
Table 4. In subgroup analysis according to age,
surgical intervention consistently reduced all-cause
mortality at one year by 45% in the <60 years age
group (HR 0.55, 95% CI 0.43 to 0.71, P < 0.001) and in
the 60 years age group (HR 0.55, 95% CI 0.43 to
0.71, P < 0.001), with no signiﬁcant interaction between surgical intervention and age (P ¼ 0.828). In
subgroup analysis according to comorbid status,
surgical intervention consistently reduced mortality
across the broad spectrum of patients with variable
comorbid levels (all P < 0.001; P-value for interaction between surgery and CCI ¼ 0.925). In subgroup
analysis according to year, there was a trend in
higher protection offered by surgery in recent years.
There were no statistically signiﬁcant survival beneﬁts associated with surgery in 2000e2003 (HR 0.66,
95% CI 0.42 to 1.05, P ¼ 0.076) and 2004e2007 (HR
0.74, 95% CI 0.51 to 1.08, P ¼ 0.120), whereas surgical
intervention reduced mortality by 56% in 2016e2019
(HR 0.44, 95% CI 0.31 to 0.64, P < 0.001). There was a
marginally signiﬁcant interaction between surgery
and year of diagnosis (P ¼ 0.065).
PAF analysis
Table 5 shows the proportion of 1-year all-cause
deaths attributable to demographics, comorbidities,
aetiology, mode of acquisition, the microbiology of
IE, and surgical intervention. Age 60 years (19.2%,
95% CI 14.5 to 23.9) and CCI 1 (14.6%, 95% CI 11.6
to 18.5) had the highest PAFs of all risk factors
considered. Other major contributors to 1-year
death included moderate/severe renal impairment
(PAF 1.8%, 95% CI 0.5 to 3.2, P ¼ 0.009) and MRSA

endocarditis (PAF 3.4%, 95% CI 2.5 to 4.3, P < 0.001).
The PAF of surgery was 7.9% (95% CI -9.5 to 6.4).
The PAF of surgical intervention signiﬁcantly
increased over the past two decades (Table 6). The
PAF for surgery in 2000e2003 and 2004e2007 were
4.4% (95% CCI -7.7 to 0.6) and 2.6% (95% CI -7.4
to 3.8), whereas the PAF for surgery increased to
12.2% (95% CI -16.1 to 6.9) in 2016e2019.

Discussion
Exploiting this territory-wide database of 5657
patients with IE, our study revealed several key
ﬁndings. Patients with IE in Hong Kong are
increasingly older, which was the most important
determinant of IE-related mortality. On the other
hand, surgical intervention was consistently associated with reduced 1-year all-cause mortality
regardless of age and comorbidities, and the mortality beneﬁts offered by surgery increased over
time.
A detailed illustration of the contributors to IE's
associated signiﬁcant mortality is depicted in Central Illustration. We found that advanced age was
the most important factor in impairing survival,
with a PAF of 19.1%. At the same time, other factors
including advanced comorbid status (quantiﬁed by
CCI 1; PAF 17.8%), renal impairment (PAF 1.9%),
healthcare-associated endocarditis (PAF 2.1%), and
MRSA (PAF 4.5%) were the other most signiﬁcant
factors contributing to worse mortality. The combination of an ageing population with more comorbidities and an increasing incidence of MRSA
infections represents a major challenge in the
management of patients with IE [24]. In contrast to
other more common microorganisms causing IE,
MRSA infections are more difﬁcult to eradicate,
predisposing IE patients to an even more prolonged
inﬂammatory load, aggravating the ‘inﬂammageing’ phenomenon that drives the poor prognosis
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Table 3. Cohort characteristics and standardized mean difference after inverse propensity of treatment weighting in patients who received vs did not
receive surgical intervention.

in IE. Infection by MRSA also mandates the use of
vancomycin, which may exacerbate renal impairment, another signiﬁcant contributor to IE patients'
high mortality rate. In addition, with the ageing
population, the prevalence of risk factors such as
hospital-acquired infections through haemodialysis
is expected to increase further, and hospital-acquired endocarditis was indeed another factor that
signiﬁcantly impaired survival. Thus, interventions

to lower the risk of iatrogenic endocarditis due to
medical care procedures, such as a more liberal
approach in using antibiotic prophylaxis in highrisk patients, should be put in place to alleviate the
burden of IE. Nevertheless, although the use of
antibiotics may prevent such hospital-acquired infections, downsides may include hastening the
emergence of bacterial resistance. Our previous
population-based study has shown that the
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Figure 1. Survival curves for 1-year mortality in patients received vs not received surgical intervention.

restriction of antibiotic prophylaxis did not result in
an increase in IE incidence, highlighting the
importance of judicious use of antibiotics and
personalized considerations. Therefore, collaborative efforts between physicians, microbiologists,
nurses, hospital administrators, and relevant allied
health professionals are needed to formulate hospital-level policies and implement interventions to
tackle these factors that lead to poor prognosis of IE.
Speciﬁcally, with the “inﬂamm-ageing” phenomenon, development of primary prevention strategies
targeted at the major risk factors (advanced age and
comorbid status), both of which are non-modiﬁable,
is eminent.
In our territory-wide cohort, surgical intervention
signiﬁcantly reduced mortality rate. Ways by which

surgery improve prognosis are multi-fold. With
direct removal of the bacterial vegetation, the
source of systemic inﬂammation can be eliminated.
The bacterial lesion can also be ‘excised’, and in the
case of MRSA endocarditis, it may imply an expedited reduction in antibiotic-resistant microbial
load. On the other hand, surgery offers immediate
reversal of valvular defect, hence preventing heart
failure and improving hemodynamic status. Surgical intervention may also be related to renal function, by means of ameliorating renal function and
reducing the exposure to potentially reno-toxic
antibiotics such as vancomycin. Nevertheless,
CDARS does not have data on blood pressure,
echocardiogram, and urine output, and future
studies are required to validate surgery's associated
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Table 4. Subgroup analysis for association between surgical intervention and 1-year all-cause mortality.

risk reduction in complications such as shock, heart
failure, and acute kidney injury.
In translating the postulated mechanisms of surgery's effects listed above into clinically signiﬁcant
beneﬁts, although limited by the retrospective nature and lack of randomisation in treatment allocation, we accounted for the bias by employing a
propensity score approach [6,23]. The ‘doublyrobust’ estimation technique was also employed to
further minimize bias in our sensitivity analysis
[6,23], which showed consistent results. In addition,
we performed subgroup analyses by stratifying patients according to age and comorbid status, and
revealed consistently signiﬁcant risk reduction in
adverse outcomes conferred by surgical intervention, regardless of age and CCI. Although patients
have aged and become more comorbid, we found
that the beneﬁts of surgery increased signiﬁcantly
over the past two decades, which can be attributed
to the increasing surgical volume and thus

improved surgical experience/technique. These results reinforced the importance of surgical intervention, as part of the treatment for IE, further
supporting the current international guidelines to
perform surgery when indicated [10,25]. However, it
is noteworthy that increasing rates of surgery was
not paralleled by a reduction in mortality rate,
which may be explained by practical barriers such
as resource limitation and refusal by surgeons/patients [6,26]. These highlight the importance of
implementing public policy changes to remove
practical barriers in order to adhere to evidencebased recommendations.
In our present study, the rate of culture-negative
endocarditis appeared high (18.9%). Reasons for the
apparently high rate of culture-negativity may
include early initiation of antibiotics (before blood
culture samples were taken), missing data, and that
patients did not meet the full modiﬁed Duke's
criteria. Indeed, although our validation exercise
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Table 5. Population attributable fraction of 1-year all-cause death.

showed high positive predictive value [6], it did not
employ the modiﬁed Duke's criteria to validate the
case diagnoses. Instead, we employed a more
pragmatic approach to validate the cases, similar to
a recent Scottish-wide cohort study [2]. While this
casts doubt on the validity of diagnoses of infective
endocarditis in our cohort of patients, the rate of
culture-negative endocarditis was in fact lower than
previous high-quality population-based cohorts
[2,4]. It was also similar to the ESC-EORP EUROENDO registry, of which 16.8% of patients were
culture-negative [27]. Other possible reasons for the
variability in microbiology between cohorts include
geographic differences, which has long been implicated in the epidemiological landscape of infective
endocarditis [6].
Table 6. Changes in population attributable fraction of surgical intervention over time.

Strengths and limitations
The current study results are merited by its study
design and data source. First, CDARS is well-known
as a validated real-world territory-wide database
with minimal risk of misinformation on diagnoses
and outcomes. Previous high-quality studies utilizing CDARS have been published [16e18]. It enables
speciﬁcation of characteristics that exhibit
geographical variation, including microbiology and
comorbidities such as rheumatic heart disease
[6,28]. The consistent results in our subgroup/
sensitivity analyses ensure generalizability of our
population-based study, which has long been a
major concern in the context of the heterogenous
populations of IE patients. The advantages of
CDARS also minimize the risk of selection bias and
ensure accurate information with adequate external
validity. Second, for the ICD codes used in the
present CDARS study, we have validated the accuracy of these codes with our validation exercise
showing comparable positive predictive value with
previous high-quality population-based studies
[2,4]. Third, instead of relying on ICD codes to
obtain information on causative organisms, we were
able to retrieve complete blood culture information
and sensitivity testing results for all patients
included in the present study. This minimizes the
proportion of patients wrongly labelled as culturenegative (due to missing ICD codes) or as other
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microbiological groups (as the ICD codes have not
been extensively validated). Fourth, we included
only incident cases of IE in our studies to avoid
unnecessary inﬂation of patients with recurrent IE.
We employed a minimum look-back period of 7
years, minimizing the risk of wrongly deﬁning
recurrent cases as incident cases [4]. Fifth, the
robustness of our ﬁndings was reinforced by the
large cohort size and advanced statistical analysis
techniques (IPTW and ‘doubly-robust’ estimation),
minimizing bias in our study results.
There are several limitations to our study. Similar
to previous studies [6,17,23], diagnostic coding in
CDARS was based on ICD-9 codes instead of ICD-10
codes; nevertheless, our validation exercise and
previous studies showed high coding accuracy
[17,18]. Although the rate of culture-negative endocarditis in our study appeared high, it was similar to
prior population-based studies [2,29], whereas discrepancies with other territory-wide studies may be
explained by geographical differences [2,4,6]. We
were unable to retrieve information on patient
presentation/symptoms, which were not available in
CDARS. Echocardiographic data, including the
valve(s) involved, vegetation size, and ejection
fraction, neuroimaging data showing the development of cerebral embolism, and patient's clinical
course such as initial response to antibiotics, were
also not available in CDARS, and future studies are
required to characterize the beneﬁts of surgery in
speciﬁc relation to these parameters.

Conclusions
We found that IE patients have become older in
the past two decades. Notably, the burden of MRSA
endocarditis, hospital-acquired endocarditis, renal
impairment, and other comorbidities were the
leading factors contributing to poor prognosis in IE.
Surgical intervention offered signiﬁcant protection
against adverse outcomes with consistent effects
across patient subgroups stratiﬁed by age and comorbid status, and we observed an increasing
temporal trend in the beneﬁts of surgery.
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